Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial

Published:2024-07 Issue: Volume:73 Page:102702
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Shi Yuankai^ORCID,Zhou Keshu,Zhou Hui,Qin Yan,Jing Hongmei,Xiang Ying,Wang Zhao,Wang Zhen,Zang Aimin,Bai Ou,Li Zhenyu,Zhang Huilai,Song Yongping,Liang Jinjin,Wei Min

Publisher

Elsevier BV

Reference24 articles.

1. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases;Li;J Diagn Concepts Pract,2012

2. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials;Casulo;Blood,2017

3. Current challenges in the management of follicular lymphoma;Yazdy;Int J Hematol Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP